BACKGROUND Previous research suggest that repeated lead-chelation therapy decelerates progression of renal insufficiency in non-diabetic (non-DM) patients with high-normal body lead burden (BLB). Study findings are limited by relatively short-term follow-up and small sample size. METHODS A total of 116 non-DM patients with chronic kidney diseases (serum creatinine level of 1.5-3.9 mg/dl), hig...

As a unique electron donor and acceptor, iron is an essential element in most biological systems. However, its chemical reactivity can result in iron potentially becoming a toxin when present in excessive quantities; accordingly, total body iron must be tightly regulated. As humans have no physiological mechanism for the elimination of excess iron, body iron is controlled mainly by the degree o...

In this case presentation, a woman with high serum levels of aluminum was treated with chelation therapy with deferoxamine and ascorbic acid. This patient was initially bedridden and the clinical situation was complicated by epileptic seizures. After the chelation therapy, the clinical condition was ameliorated and the therapy continued without the correlation to aluminum serum levels. The role...

BACKGROUND The use of repeated intravenous infusions of EDTA, which has become known as "chelation therapy," has been promoted for treating intermittent claudication as well as a wide range of other disorders. Multiple reports of excellent results in large numbers of patients have encouraged the use of this regimen. The lack of well-controlled studies substantiating the benefits of this treatme...

background: thalassemia is a series of hemoglobinopathies in which the production of perfect hemoglobin is completely or partially suppressed. using injectable iron chelators have been dominating treatment for the iron overload caused by recurrent blood transfusions in thalassemic patients, however, a new oral iron chelating drug (exjade) have been recently introduced and might be cost effectiv...

Trial to Assess Chelation Therapy (TACT) was a prospective, randomized, double-blind, placebo-controlled trial designed to evaluate the effect of ethylenediaminetetraacetic acid-based intravenous chelation therapy on cardiovascular outcomes. A total of 1708 stable patients >50 years of age with a previous myocardial infarction were enrolled at 134 North American sites and followed for a median ...

OBJECTIVES There is a need to remove excess iron with iron chelation therapy (ICT) to avoid the serious clinical sequelae associated with iron overload in patients with beta thalassemia major (BTM) and sickle cell anemia (SCA). Due to the effects of the diseases and their treatments, ICT is still a major reason for unsatisfactory compliance. The aim of this single-center observational study was...